Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA’s In-Person Foreign Inspections Remain On House Appropriators’ Minds

Executive Summary

The House Appropriations Committee also does not want the agency to become too dependent on alternative inspection tools.

You may also be interested in...



US FDA’s Regulatory Affairs Office Building Case For More User Fee Funding

ORA represented only a small fraction of the user fee programs’ costs in recent years, but wants to show its importance to the review process.

Domestic In-Person Inspection Work Could Be Back To Normal This Summer, Woodcock Says

Foreign facility visits may take longer to reach usual levels because of the ongoing coronavirus outbreaks in other countries.

US FDA’s Inspection Volume Projected To Return To Normal Levels In FY 2022 As Backlog Looms

Additional hiring in FDA’s FY 2022 budget request also is expected to help address the inspections delayed by the coronavirus pandemic.

Related Content

Topics

UsernamePublicRestriction

Register

PS144592

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel